Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹11,777 Cr
Revenue (TTM)
₹4,482 Cr
Net Profit (TTM)
₹502 Cr
ROE
13.5 %
ROCE
15.7 %
P/E Ratio
23.5
P/B Ratio
3.2
Industry P/E
37.31
EV/EBITDA
13
Div. Yield
0.3 %
Debt to Equity
0.1
Book Value
₹153.1
EPS
₹19.7
Face value
1
Shares outstanding
242,643,716
CFO
₹3,170.43 Cr
EBITDA
₹5,318.02 Cr
Net Profit
₹2,968.84 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Granules India
| -18.2 | -5.3 | -2.3 | 3.4 | 26.0 | 18.6 | 19.0 |
|
BSE Healthcare
| -4.6 | 0.9 | 5.1 | 16.9 | 27.0 | 21.6 | 10.3 |
|
BSE Mid Cap
| -2.1 | 0.6 | 10.4 | -1.0 | 28.7 | 28.8 | 15.8 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Granules India
| 43.8 | 27.2 | -5.2 | -6.4 | 188.9 | 35.6 | -34.7 |
|
BSE Mid Cap
| 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 | -13.3 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Granules India
|
484.8 | 11,776.7 | 4,481.6 | 501.5 | 16.1 | 13.4 | 23.5 | 3.2 |
| 933.0 | 18,318.7 | 6,672.1 | 582.0 | 10.9 | 11.6 | 31.4 | 3.5 | |
| 980.0 | 37,594.9 | 1,197.6 | 264.8 | 24.9 | 14.6 | 140.3 | 22.0 | |
| 1,639.1 | 45,970.5 | 13,321.7 | 1,047.1 | 14.0 | 14.6 | 43.9 | 5.2 | |
| 1,131.6 | 18,135.0 | 7,234.5 | 836.8 | 11.1 | 7.9 | 21.6 | 2.9 | |
| 646.0 | 34,801.7 | 5,554.0 | 354.4 | 11.3 | 8.3 | 97.1 | 7.8 | |
| 871.2 | 15,639.0 | 4,429.5 | 1,883.4 | 44.3 | 25.6 | 8.3 | 2.1 | |
| 194.6 | 25,913.7 | 9,151.2 | 18.2 | 6.9 | 1.1 | 284.4 | 3.2 | |
| 630.2 | 25,475.8 | 3,642.4 | 496.2 | 16.6 | 10.4 | 51.3 | 5.4 | |
| 1,723.0 | 27,384.5 | 3,012.0 | -57.0 | 5.8 | -1.2 | -- | 6.3 |
Stock Rating update, March 15, 2024
2 min read•By Value Research
Why is this paracetamol maker bleeding?
4 min read•By Hemkesh Khattar
Companies falling short of cash
2 min read•By Rajan Gulati
1 min read•By Research Desk
1 min read•By Research Desk
6 min read•By Value Research
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally.... The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; and other products for oncology. The Company also exports its products. Granules India Limited was founded in 1984 and is based in Hyderabad, India. Read more
Incorporated
1991
Chairman
Krishna Prasad Chigurupati
Managing Director
Krishna Prasad Chigurupati
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Granules India Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Granules India Ltd stood at ₹ 6,253 Cr as on 31-Mar-25
The share price of Granules India Ltd is ₹484.75 (NSE) and ₹484.70 (BSE) as of 20-Jun-2025 14:34 IST. Granules India Ltd has given a return of 26.01% in the last 3 years.
Granules India Ltd has a market capitalisation of ₹ 11,777 Cr as on 20-Jun-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Granules India Ltd is 3.17 times as on 20-Jun-2025, a 10% discount to its peers’ median range of 3.53 times.
The P/E ratio of Granules India Ltd is 23.48 times as on 20-Jun-2025, a 37% discount to its peers’ median range of 37.31 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Granules India Ltd and enter the required number of quantities and click on buy to purchase the shares of Granules India Ltd.
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; and other products for oncology. The Company also exports its products. Granules India Limited was founded in 1984 and is based in Hyderabad, India.
The promoters of Granules India Ltd are KRISHNA PRASAD CHIGURUPATI and CHIGURUPATI UMA DEVI. They collectively own 35.47 per cent of the total equity. The chairman of the company is Krishna Prasad Chigurupati
There is no promoter pledging in Granules India Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
47,119
|
|
|
38,404
|
|
|
35,992
|
|
|
28,881
|
|
|
26,612
|
|
|
26,292
|
|
|
19,643
|
|
|
17,428
|
|
|
16,345
|
| Granules India Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
13.38
|
|
Operating margin(%)
|
16.06
|
|
Net Margin(%)
|
11.16
|
|
Dividend yield(%)
|
0.31
|
Yes, TTM profit after tax of Granules India Ltd was ₹502 Cr.
₹4.45
(
